Algert Global LLC Revolution Medicines, Inc. Transaction History

Algert Global LLC

$3.72 Billion
Q3 2024

A detailed history of Algert Global LLC transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, Algert Global LLC holds 40,048 shares of RVMD stock, worth $2.26 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

40,048

Previous 40,048 -0.0%

Holding current value

$2.26 Million

Previous $1.55 Million 16.86%

% of portfolio

0.05%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$30.14 - $40.68 $1.01 Million - $1.37 Million	33,588 Added 519.94%	40,048 $1.55 Million
Q1 2024 May 14, 2024	SELL	$26.56 - $33.55 $375,558 - $474,396	-14,140 Reduced 68.64%	6,460 $208,000
Q4 2023 Feb 14, 2024	BUY	$18.35 - $34.12 $378,010 - $702,872	20,600 New	20,600 $591,000
Q1 2023 May 12, 2023	SELL	$20.76 - $30.09 $1.15 Million - $1.66 Million	-55,163 Reduced 50.24%	54,627 $1.18 Million
Q4 2022 Feb 13, 2023	SELL	$17.68 - $25.53 $323,897 - $467,709	-18,320 Reduced 14.3%	109,790 $2.62 Million
Q3 2022 Nov 15, 2022	BUY	$17.46 - $26.0 $1.83 Million - $2.72 Million	104,730 Added 447.95%	128,110 $2.53 Million
Q2 2022 Aug 15, 2022	BUY	$14.54 - $27.17 $339,945 - $635,234	23,380 New	23,380 $456,000
Q4 2021 Feb 14, 2022	SELL	$24.35 - $33.7 $371,873 - $514,666	-15,272 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$23.95 - $33.41 $109,738 - $153,084	4,582 Added 42.86%	15,272 $420,000
Q2 2021 Aug 13, 2021	SELL	$29.0 - $47.44 $4,640 - $7,590	-160 Reduced 1.47%	10,690 $339,000
Q1 2021 May 14, 2021	BUY	$37.21 - $54.43 $25,079 - $36,685	674 Added 6.62%	10,850 $498,000
Q4 2020 Feb 12, 2021	BUY	$30.19 - $45.49 $307,213 - $462,906	10,176 New	10,176 $403,000

Others Institutions Holding RVMD

# of Institutions

266

Shares Held

161M

Call Options Held

260K

Put Options Held

620K

View Full List

About Revolution Medicines, Inc.

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $4.95B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

More about RVMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

News

Stay updated on Algert Global LLC with notifications on news.

Account

Algert Global LLC Revolution Medicines, Inc. Transaction History